Skip to main content
. 2022 Mar 18;12:818679. doi: 10.3389/fonc.2022.818679

Table 3.

AEs in ≥20% of all patients of any grade and all patients of grade ≥3: mITT population.

AEs by Preferred Term Number of patients (N = 10)
Any grade Grade 3 Grade 4
Leukopenia/white blood cell count decreased 10 0 10
Lymphopenia/lymphocyte count decreased 10 0 10
Neutropenia/neutrophil count decreased 10 0 10
Anemia/red blood cell count decreased 9 9 0
Thrombocytopenia/platelet count decreased 6 1 4
Hyponatremia 6 5 0
Hypophosphatemia 4 1 1
Fatigue 7 2 0
Tumor pain 3 2 0
Rash 5 0 1
Pyrexia 6 1 0
Decreased appetite 5 1 0
Constipation 4 1 0
Hypotension 4 1 0
Hypocalcemia 3 1 0
Abdominal pain 2 1 0
Acute kidney injury 2 1 0
CRS 2 1 0
Dyspnea 2 1 0

AE, adverse event; CRS, cytokine release syndrome; mITT, modified intent-to-treat.